DE69928932D1 - Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung - Google Patents

Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung

Info

Publication number: DE69928932D1
Authority: DE; Germany
Prior art keywords: antisense oligonucleotides; present; neoplastic cell; treatment; receptors
Prior art date: 1998-06-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69928932T

Other languages

English (en)

Other versions

DE69928932T2 (de

Inventor

Paolo Renzi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Topigen Pharmaceuticals Inc

Original Assignee

Topigen Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-17

Filing date

1999-06-17

Publication date

2006-01-19

1999-06-17 Application filed by Topigen Pharmaceuticals Inc filed Critical Topigen Pharmaceuticals Inc

2006-01-19 Publication of DE69928932D1 publication Critical patent/DE69928932D1/de

2006-09-07 Application granted granted Critical

2006-09-07 Publication of DE69928932T2 publication Critical patent/DE69928932T2/de

2019-06-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
206010003645 Atopy Diseases 0.000 title abstract 2
210000005170 neoplastic cell Anatomy 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
206010014950 Eosinophilia Diseases 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 2
208000006673 asthma Diseases 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
150000007523 nucleic acids Chemical group 0.000 abstract 2
102000004499 CCR3 Receptors Human genes 0.000 abstract 1
108010017316 CCR3 Receptors Proteins 0.000 abstract 1
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 abstract 1
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
102000004559 Interleukin-13 Receptors Human genes 0.000 abstract 1
108010017511 Interleukin-13 Receptors Proteins 0.000 abstract 1
102000010790 Interleukin-3 Receptors Human genes 0.000 abstract 1
108010038452 Interleukin-3 Receptors Proteins 0.000 abstract 1
102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 1
108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 1
102000010786 Interleukin-5 Receptors Human genes 0.000 abstract 1
108010038484 Interleukin-5 Receptors Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69928932T 1998-06-17 1999-06-17 Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung Expired - Lifetime DE69928932T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002235420A CA2235420A1 (en)	1998-06-17	1998-06-17	Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
CA2235420		1998-06-17
PCT/CA1999/000572 WO1999066037A2 (en)	1998-06-17	1999-06-17	Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Publications (2)

Publication Number	Publication Date
DE69928932D1 true DE69928932D1 (de)	2006-01-19
DE69928932T2 DE69928932T2 (de)	2006-09-07

Family

ID=4162352

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69928932T Expired - Lifetime DE69928932T2 (de)	1998-06-17	1999-06-17	Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung

Country Status (10)

Country	Link
US (3)	US6822087B1 (de)
EP (1)	EP1088065B1 (de)
JP (1)	JP4612188B2 (de)
AT (1)	ATE312911T1 (de)
AU (1)	AU758447B2 (de)
CA (1)	CA2235420A1 (de)
DE (1)	DE69928932T2 (de)
MX (1)	MXPA00012703A (de)
NZ (1)	NZ509308A (de)
WO (1)	WO1999066037A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2235420A1 (en) *	1998-06-17	1999-12-17	Paolo Renzi	Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6566132B1 (en) *	2001-04-26	2003-05-20	Isis Pharmaceuticals, Inc.	Antisense modulation of Interferon gamma receptor 1 expression
CA2451738C (en)	2001-07-06	2013-09-17	Topigen Pharmaceutique Inc.	Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine
WO2004011613A2 (en) *	2002-07-29	2004-02-05	Epigenesis Pharmaceuticals, Inc.	Composition & methods for treatment and screening
AU2004275903B2 (en)	2003-09-29	2012-04-12	Topigen Pharmaceutique Inc.	Oligonucleotide compositions and methods for treating disease including inflammatory conditions
TW200526777A (en) *	2003-11-12	2005-08-16	Combinatorx Inc	Combinations for the treatment of proliferative diseases
US7928216B2 (en) *	2004-04-29	2011-04-19	Yale University	Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
WO2006045202A1 (en) *	2004-10-29	2006-05-04	Topigen Pharmaceuticals Inc.	Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
AU2006216514C1 (en) *	2005-02-25	2012-09-27	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to IL-4R alpha
AU2006299345A1 (en) *	2005-10-03	2007-04-12	Isis Pharmaceuticals, Inc.	Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
WO2007076366A2 (en) *	2005-12-20	2007-07-05	Isis Pharmaceuticals, Inc	Double stranded nucleic acid molecules targeted to il-4 receptor alpha
KR20090035662A (ko)	2006-05-19	2009-04-10	토피겐 파마슈티컬스 인코포레이티드	포스포디에스테라아제의 발현에 영향을 미치는 올리고누클레오티드
KR20110017881A (ko) *	2008-05-15	2011-02-22	토피겐 파마슈티컬스 인코포레이티드	감염 및 신생세포 증식 치료용 올리고뉴클레오티드
US8341614B2 (en) *	2008-06-06	2012-12-25	Apple Inc.	Memory management for closures
WO2012024260A2 (en)	2010-08-16	2012-02-23	The Trustees Of Columbia University In The City Of New York	Intranasal delivery of cell permeant therapeutics
DK3050574T3 (da)	2015-01-28	2020-01-20	Univ Bordeaux	Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
AU2018250214B2 (en)	2017-04-05	2021-09-16	Alkahest, Inc.	Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
US12221463B2 (en)	2020-08-07	2025-02-11	The Board Of Regents Of The University Of Oklahoma	Method of promoting wound healing by inhibiting CCR3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6806061B1 (en)	1995-01-19	2004-10-19	Children's Medical Center Corporation	G protein-coupled receptor gene and methods of use therefor
US5874211A (en)	1995-04-13	1999-02-23	Incyte Pharmaceuticals, Inc.	Chemokine expressed in eosinophils
FR2734147B1 (fr)	1995-05-19	1997-10-10	Klein Jean Michel	Dispositif d'osteosynthese implantable
FR2735984B1 (fr)	1995-06-30	1997-09-19	Inst Nat Sante Rech Med	Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
FR2742156A1 (fr) *	1995-12-06	1997-06-13	Sanofi Sa	Polypeptide recepteur de l'il-13
US6265184B1 (en) *	1995-12-20	2001-07-24	Icos Corporation	Polynucleotides encoding chemokine receptor 88C
WO1997023244A1 (en)	1995-12-22	1997-07-03	Smithkline Beecham Corporation	Use of antisene oligodeoxynucleotides to produce truncated proteins
AUPN780096A0 (en) *	1996-01-30	1996-02-22	Medvet Science Pty. Ltd.	Cytokine antagonists and agonists
EP0906424A2 (de)	1996-04-26	1999-04-07	Incyte Pharmaceuticals, Inc.	Kombinierte lymphozytrezeptoren (mmlr-ccr), von der chemokin rezeptoren familie
EP1012190A4 (de)	1996-04-26	2004-04-28	Merck & Co Inc	Eotaxinrezeptor aus Eosinophilen
CA2304312A1 (en) *	1997-09-17	1999-03-25	East Carolina University	Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
CA2235420A1 (en) *	1998-06-17	1999-12-17	Paolo Renzi	Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

1998
- 1998-06-17 CA CA002235420A patent/CA2235420A1/en not_active Abandoned
1999
- 1999-06-17 WO PCT/CA1999/000572 patent/WO1999066037A2/en active IP Right Grant
- 1999-06-17 AT AT99927615T patent/ATE312911T1/de not_active IP Right Cessation
- 1999-06-17 AU AU44932/99A patent/AU758447B2/en not_active Ceased
- 1999-06-17 US US09/719,737 patent/US6822087B1/en not_active Expired - Lifetime
- 1999-06-17 MX MXPA00012703A patent/MXPA00012703A/es not_active IP Right Cessation
- 1999-06-17 EP EP99927615A patent/EP1088065B1/de not_active Expired - Lifetime
- 1999-06-17 DE DE69928932T patent/DE69928932T2/de not_active Expired - Lifetime
- 1999-06-17 NZ NZ509308A patent/NZ509308A/en not_active IP Right Cessation
- 1999-06-17 JP JP2000554846A patent/JP4612188B2/ja not_active Expired - Fee Related
2004
- 2004-10-04 US US10/958,204 patent/US7629324B2/en not_active Expired - Fee Related
2009
- 2009-10-26 US US12/605,737 patent/US20100286239A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2002518007A (ja)	2002-06-25
US6822087B1 (en)	2004-11-23
EP1088065A2 (de)	2001-04-04
ATE312911T1 (de)	2005-12-15
CA2235420A1 (en)	1999-12-17
US20100286239A1 (en)	2010-11-11
NZ509308A (en)	2003-05-30
AU4493299A (en)	2000-01-05
EP1088065B1 (de)	2005-12-14
US20050282762A1 (en)	2005-12-22
US7629324B2 (en)	2009-12-08
MXPA00012703A (es)	2003-07-14
WO1999066037A2 (en)	1999-12-23
JP4612188B2 (ja)	2011-01-12
AU758447B2 (en)	2003-03-20
WO1999066037A3 (en)	2000-04-20
DE69928932T2 (de)	2006-09-07

Publication	Publication Date	Title
DE69928932D1 (de)	2006-01-19	Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung
Gouze et al.	2002	Glucosamine modulates IL‐1‐induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF‐κB pathway
Kang et al.	2000	Transcriptional inactivation of the tissue inhibitor of metalloproteinase‐3 gene by dna hypermethylation of the 5'‐CpG island in human gastric cancer cell lines
ATE286053T1 (de)	2005-01-15	Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE241358T1 (de)	2003-06-15	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
NO965080L (no)	1996-11-28	Antisens oligonukleotidmodulering av genekspresjon
ATE265219T1 (de)	2004-05-15	Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
ATE311371T1 (de)	2005-12-15	Nicht-peptide inhibitoren von vla-4 abhängiger zellbindung für die behandlung von entzündungen, autoimmune krankheiten und atemstörungen
DE69722681D1 (de)	2003-07-10	Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69927960D1 (de)	2005-12-01	Epiallopregnanolon zur behandlung von krankheiten des cns
ATE337780T1 (de)	2006-09-15	Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE69826695D1 (de)	2004-11-04	Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE365042T1 (de)	2007-07-15	Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69736432D1 (de)	2006-09-14	Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
ATE369844T1 (de)	2007-09-15	Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
DE60234873D1 (de)	2010-02-04	Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
DE69737397D1 (de)	2007-04-05	Verwendung von mif-antagonisten zur krebstherapie
Brzoska et al.	1999	Molecular basis of the α‐MSH/IL‐1 antagonism
ATE222119T1 (de)	2002-08-15	Verwendung von erythropoietin zur behandlung von multiple myelom
DE60307237D1 (de)	2006-09-14	Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
WO1998011234A3 (en)	1998-07-09	Human protein kinases
ATE209891T1 (de)	2001-12-15	Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE60023139D1 (de)	2006-02-23	Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
DE59900286D1 (de)	2001-10-31	Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE423129T1 (de)	2009-03-15	Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Legal Events

Date	Code	Title	Description
2007-01-04	8364	No opposition during term of opposition
2008-05-15	8328	Change in the person/name/address of the agent	Representative=s name: GROSSE, SCHUMACHER, KNAUER, VON HIRSCHHAUSEN, 8033